跳至主要内容
临床试验/NCT01902615
NCT01902615已完成不适用

Multicenter, Observational, Retrospective Study to Assess the Therapeutic Effectiveness of a Strategy of Induction With Enfuvirtide Within an Optimized Regimen of Antiretroviral Drugs (ARV) in Patients Infected With HIV-1 in Routine Clinical Practice

Hoffmann-La Roche0 个研究点目标入组 58 人开始时间: 2001年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
58
主要终点
Response rate: Proportion of patients with reduction of viral load to < 50 copies/ml

研究概览

简要总结

This multicenter, retrospective, observational study will evaluate the therapeutic effectiveness of a strategy of induction with Fuzeon (enfuvirtide) within an optimized regimen of antiretroviral drugs in patients with HIV-1 infection in routine clinical practice.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients, >/= 18 years of age
  • HIV-1+ infection
  • Patients with a viral load > 50 copies/ml who have received induction treatment with Fuzeon in combination with antiretroviral treatment
  • Naïve for Fuzeon at initiation of induction treatment
  • Antiretroviral treatment of at least 12 months duration

排除标准

  • Patients who did not receive Fuzeon treatment

结局指标

主要结局

Response rate: Proportion of patients with reduction of viral load to < 50 copies/ml

时间窗: approximately 24 months

次要结局

  • Duration of treatment with Fuzeon(approximately 24 months)
  • Time to undetectability, defined as time from initiation of treatment to first observation of viral load < 50 copies/ml(approximately 24 months)
  • Safety: Incidence of adverse events(approximately 24 months)
  • Treatment regimen: Antiretroviral drugs used(approximately 24 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验